KindredBio Leadership

Richard Chin, MD

Richard Chin, MD

Co-Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

Wendy Wee

Wendy Wee

Chief Financial Officer

Wendy Wee is a financial executive with over 30 years of public company experience in both the biotechnology and high-tech industries. From 2002 to 2014, Wendy served in various positions at Telik — a biotechnology company focused on oncology — including vice president of finance, principal financial and accounting officer, and controller. Prior to Telik, Wendy was the senior director of finance and controller at Connetics, Inc., a biotechnology company focused on dermatological diseases. Before Connetics, she held various management positions at companies like Silicon Graphics, Inc., MIPS Computer Systems, and Unisys Corporation.

Hangjun Zhan, PhD

Hangjun Zhan, PhD

Chief Scientific Officer

Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotech industry. He joined KindredBio in February 2014 to lead biologics research. Previously, Dr. Zhan served as an executive member at Aragen Biosciences and led their protein sciences group. Prior to that, he established and headed up the Protein Biochemistry Group at Exelixis, including protein expression, fermentation/bioproduction, protein purification/biophysics, and proteomics. His team’s work led to more than 20 drug candidates. He has also previously served as group leader of Protein Chemistry at Axys Biopharmaceuticals (Celera) where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School; there, he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. While earning his Ph.D. from the University of Washington, he discovered a novel chemical-signaling molecule involved in bacterial invasion.

Jenna (Hahn) Mutch

Jenna (Hahn) Mutch

Vice President of Commercial

Specializing in the companion animal and equine industries, Jenna Hahn has over 15 years of sales, marketing, and product launch experience. Jenna has worked in the veterinary division of Hill’s Pet Nutrition and Merck and for animal health companies such as Merial and IDEXX. She has consulted for many small businesses in the pet and equine industry, helping to bring their products to the veterinary market. She currently sits on the board of directors for the Northern California Association of Equine Practitioners. Jenna is very active in the veterinary community and has spent her career working directly with veterinarians and their staffs to help improve the quality of life for the animals we love.

Katja Buhrer

Katja Buhrer

Chief of Staff, VP of Corporate Development and Investor Relations

Katja Buhrer has a diverse background in investor relations advisory, capital markets, and financial reporting. Before joining KindredBio, she was managing director at the investor relations consultancy MBS Value Partners. In this role, Katja devised and executed investor relations strategies for the firm’s clients and oversaw their investment community communications. Previously, Katja worked at Citi in capital markets and sales and trading. She was also a reporter, editor, and columnist at the Financial Review. During this time, Katja was a frequent author of front-page stories and had a personal weekly capital markets column.